Gannet BioChem has filed a Type II Drug Master File (DMF) under its Arab, Alabama facility (FEI 3006223361) for PEG propionaldehyde 20K. The filing supports the development and commercialisation of pegfilgrastim biosimilars. The company operates in life sciences manufacturing and
Gannet BioChem, a specialty chemical Contract Development and Manufacturing Organization (CDMO), has announced key leadership appointments following its acquisition by Ampersand Capital Partners. Nicholas Shackley has been named Chief Executive Officer (CEO), while Chris Edwards joins as Chief Financial Officer
Ampersand Capital Partners, a private equity firm with a focus on life sciences and healthcare, has completed the acquisition of Nektar Therapeutics’ PEGylation reagent manufacturing business. The newly rebranded entity, Gannet BioChem, will operate from its established facility in Huntsville,
